(Q38414983)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20803611%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20803611%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20803611%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Bryan Teruya

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20803611%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Susan Repertinger

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20803611%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Pamela Ulmer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20803611%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Jill Hagenkord

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20803611%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Zoran Gatalica

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20803611%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

English

0 references

publication date

27 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20803611%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20803611%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20803611%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20803611%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

48-53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20803611%20AND%20SRC:MED&resulttype=core&format=json

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Treatment of metastatic breast cancer: looking towards the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Evaluating HER2 amplification and overexpression in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Copy number alterations that predict metastatic capability of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

Cardiac toxicity of ErbB2-targeted therapies: what do we know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

7 January 2021

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

7 January 2021

EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

7 January 2021

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

7 January 2021

Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

7 January 2021

Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25580

7 January 2021

Identifiers

DOI

10.1002/CNCR.25580

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20803611%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference